Iron Substitution After Upper Gastro-Intestinal Bleeding
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The trial is a double-blind randomized trial designed to examine whether compliant iron
therapy (intravenous or oral) for 3 months after discharge increases hemoglobin levels more
and faster than no treatment - in patients with acute bleeding from upper gastrointestinal
tract. The trial will include 126 patients at Aarhus University Hospital. In addition to
efficacy assessment quality of life assessment and health economic calculations between the
treatments will be compared.
Phase:
Phase 4
Details
Lead Sponsor:
University of Aarhus
Collaborators:
GCP-unit at Aarhus University Hospital, Aarhus, Denmark Vifor Pharma